Surveillance, Epidemiology, and End Results Program National Center for Health Statistics. Cancer Stat Facts: Female breast cancer. 2019. https://seer.cancer.gov/statfacts/html/breast.html.

Burstein HJ, Temin S, Anderson H, Buchholz TA, Davidson NE, Gelmon KE, et al. Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: American Society of Clinical Oncology clinical practice guideline focused update. J Clin Oncol. 2014;32:2255–69.

Article  PubMed  PubMed Central  Google Scholar 

Gradishar WJ, Moran MS, Abraham J, Aft R, Agnese D, Allison KH, et al. Breast cancer, version 3.2022, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw. 2022;20:691–722.

Article  Google Scholar 

Davies C, Godwin J, Gray R, Clarke M, Cutter D, Darby S, et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet. 2011;378:771–84.

Article  CAS  PubMed  Google Scholar 

Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. Lancet. 2015;386:1341–52.

Article  Google Scholar 

Mansell J, Monypenny IJ, Skene AI, Abram P, Carpenter R, Gattuso JM, et al. Patterns and predictors of early recurrence in postmenopausal women with estrogen receptor-positive early breast cancer. Breast Cancer Res Treat. 2009;117:91–8.

Article  CAS  PubMed  Google Scholar 

Cheng L, Swartz MD, Zhao H, Kapadia AS, Lai D, Rowan PJ, et al. Hazard of recurrence among women after primary breast cancer treatment-a 10-year follow-up using data from SEER-Medicare. Cancer Epidemiol Biomark Prev. 2012;21:800–9.

Article  Google Scholar 

Niravath P. Aromatase inhibitor-induced arthralgia: a review. Ann Oncol. 2013;24:1443–9.

Article  CAS  PubMed  Google Scholar 

Mao JJ, Stricker C, Bruner D, Xie S, Bowman MA, Farrar JT, et al. Patterns and risk factors associated with aromatase inhibitor-related arthralgia among breast cancer survivors. Cancer. 2009;115:3631–9.

Article  CAS  PubMed  Google Scholar 

Runowicz CD, Leach CR, Henry NL, Henry KS, Mackey HT, Cowens-Alvarado RL, et al. American Cancer Society/American Society of Clinical Oncology Breast Cancer Survivorship Care Guideline. CA Cancer J Clin. 2016;66:43–73.

Article  PubMed  Google Scholar 

Partridge AH, LaFountain A, Mayer E, Taylor BS, Winer E, Asnis-Alibozek A. Adherence to initial adjuvant anastrozole therapy among women with early-stage breast cancer. J Clin Oncol. 2008;26:556–62.

Article  CAS  PubMed  Google Scholar 

Henry NL, Azzouz F, Desta Z, Li L, Nguyen AT, Lemler S, et al. Predictors of aromatase inhibitor discontinuation as a result of treatment-emergent symptoms in early-stage breast cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2012;30:936–42.

Article  CAS  Google Scholar 

Dezentjé VO, van Blijderveen NJ, Gelderblom H, Putter H, van Herk-Sukel MP, Casparie MK, et al. Effect of concomitant CYP2D6 inhibitor use and tamoxifen adherence on breast cancer recurrence in early-stage breast cancer. J Clin Oncol. 2010;28:2423–9.

Article  PubMed  Google Scholar 

Weaver KE, Camacho F, Hwang W, Anderson R, Kimmick G. Adherence to adjuvant hormonal therapy and its relationship to breast cancer recurrence and survival among low-income women. Am J Clin Oncol. 2013;36:181–7.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Makubate B, Donnan PT, Dewar JA, Thompson AM, McCowan C. Cohort study of adherence to adjuvant endocrine therapy, breast cancer recurrence, and mortality. Br J Cancer. 2013;108:1515–24.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Font R, Espinas JA, Barnadas A, Izquierdo A, Galceran J, Saladie F, et al. Influence of adherence to adjuvant endocrine therapy on disease-free and overall survival: a population-based study in Catalonia, Spain. Breast Cancer Res Treat. 2019;175:733–40.

Article  CAS  PubMed  Google Scholar 

Barron TI, Cahir C, Sharp L, Bennett K. A nested case-control study of adjuvant hormonal therapy persistence and compliance, and early breast cancer recurrence in women with stage I-III breast cancer. Br J Cancer. 2013;109:1513–21.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lee Y, Park YR, Lee JS, Lee SB, Chung IY, Son BH, et al. Prescription refill gap of endocrine treatment from electronic medical records as a prognostic factor in breast cancer patients. J Breast Cancer. 2019;22:86–95.

Article  PubMed  PubMed Central  Google Scholar 

McCowan C, Wang S, Thompson AM, Makubate B, Petrie DJ. The value of high adherence to tamoxifen in women with breast cancer: a community-based cohort study. Br J Cancer. 2013;109:1172–80.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Shrank WH, Patrick AR, Brookhart MA. Healthy user and related biases in observational studies of preventive interventions: a primer for physicians. J Gen Intern Med. 2011;26:546–50.

Article  PubMed  PubMed Central  Google Scholar 

Nagin DS, Jones BL, Passos VL, Tremblay RE. Group-based multi-trajectory modeling. Stat Methods Med Res. 2018;27:2015–23.

Article  PubMed  Google Scholar 

Nagin DS, Odgers CL. Group-based trajectory modeling in clinical research. Annu Rev Clin Psychol. 2010;6:109–38.

Article  PubMed  Google Scholar 

Warren JL, Klabunde CN, Schrag D, Bach PB, Riley GF. Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population. Med Care. 2002;40:Iv-3–18.

Article  Google Scholar 

Potosky AL, Riley GF, Lubitz JD, Mentnech RM, Kessler LG. Potential for cancer related health services research using a linked Medicare-tumor registry database. Med Care. 1993;31:732–48.

Article  CAS  PubMed  Google Scholar 

Mues KE, Liede A, Liu J, Wetmore JB, Zaha R, Bradbury BD, et al. Use of the Medicare database in epidemiologic and health services research: a valuable source of real-world evidence on the older and disabled populations in the US. Clin Epidemiol. 2017;9:267–77.

Article  PubMed  PubMed Central  Google Scholar 

Division of Cancer Control and Population Sciences. SEER-Medicare linked data resource. 2023. https://healthcaredelivery.cancer.gov/seermedicare/.

Health Resources and Services Administration. Area health resources files. 2022. https://data.hrsa.gov/.

Wei YJ, Palumbo FB, Simoni-Wastila L, Shulman LM, Stuart B, Beardsley R, et al. Antiparkinson drug use and adherence in medicare part D beneficiaries with Parkinson’s disease. Clin Ther. 2013;35:1513–25.e1511.

Article  PubMed  Google Scholar 

Wei YJ, Simoni-Wastila L, Albrecht JS, Huang TY, Moyo P, Khokhar B, et al. The association of antidepressant treatment with COPD maintenance medication use and adherence in a comorbid Medicare population: a longitudinal cohort study. Int J Geriatr Psychiatry. 2018;33:e212–20.

Article  PubMed  Google Scholar 

Dong YH, Choudhry NK, Krumme A, Lee MP, Wu LC, Lai MS, et al. Impact of hospitalization on medication adherence estimation in claims data. J Clin Pharm Ther. 2017;42:318–28.

Article  CAS  PubMed  Google Scholar 

Michaelson JS, Halpern E, Kopans DB. Breast cancer: computer simulation method for estimating optimal intervals for screening. Radiology. 1999;212:551–60.

Article  CAS  PubMed  Google Scholar 

Nau D. Pharmacy quality alliance adherence measures. 2019. https://www.pqaalliance.org/adherence-measures.

Peterson AM, Nau DP, Cramer JA, Benner J, Gwadry-Sridhar F, Nichol M. A checklist for medication compliance and persistence studies using retrospective databases. Value Health. 2007;10:3–12.

Article  PubMed  Google Scholar 

Choudhry NK, Shrank WH, Levin RL, Lee JL, Jan SA, Brookhart MA, et al. Measuring concurrent adherence to multiple related medications. Am J Manag Care. 2009;15:457–64.

PubMed  PubMed Central  Google Scholar 

Chang AA. SAS macro to calculate the PDC adjustment of inpatient stays. SAS Global Forum Proceedings. 2015. https://support.sas.com/resources/papers/proceedings15/3560-2015.pdf

Centers for Medicare & Medicaid Services. Physician Quality Reporting System Measures Specifications Manual for Claims and Registry Reporting of Individual Measures. Baltimore: CMS; 2011.

Schwarz G. Estimating the dimension of a model. Ann Stat. 1978:461–4.

Chubak J, Yu O, Pocobelli G, Lamerato L, Webster J, Prout MN, et al. Administrative data algorithms to identify second breast cancer events following early-stage invasive breast cancer. J Natl Cancer Inst. 2012;104:931–40.

Article  PubMed  PubMed Central  Google Scholar 

Winn AN, Dusetzina SB. The association between trajectories of endocrine therapy adherence and mortality among women with breast cancer. Pharmacoepidemiol Drug Saf. 2016;25:953–9.

Article  CAS  PubMed  Google Scholar 

Chien HC, Kao Yang YH, Kwoh CK, Chalasani P, Wilson DL, Lo-Ciganic WH. Aromatase inhibitors and risk of arthritis and carpal tunnel syndrome among taiwanese women with breast cancer: a nationwide claims data analysis. J Clin Med. 2020;9:566.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mausbach BT, Schwab RB, Irwin SA. Depression as a predictor of adherence to adjuvant endocrine therapy (AET) in women with breast cancer: a systematic review and meta-analysis. Breast Cancer Res Treat. 2015;152:239–46.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Haskins CB, McDowell BD, Carnahan RM, Fiedorowicz JG, Wallace RB, Smith BJ, et al. Impact of preexisting mental illness on breast cancer endocrine therapy adherence. Breast Cancer Res Treat. 2019;174:197–208.

Article  CAS  PubMed